Radiation plus anlotinib for lung cancer brain spread
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer
- You have 5 or fewer brain metastases, and you can tolerate a focused radiation treatment
- You can take an oral medication (anlotinib) along with radiation
- You have not had recent bleeding or blood-related problems
- Your overall health is good enough for this therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether giving brain radiation early or later, along with almonertinib (a targeted pill), works better for people with EGFR-mutated non-small cell lung cancer that has a small number of brain metastases. It aims to control brain disease while checking safety and effectiveness in a carefully selected group.
This study tests a combination of two drugs (SKB264 and anlotinib) for advanced non-small cell lung cancer that has spread to the liver and stopped responding to previous EGFR-targeted therapy. The goal is to see if this combination can slow or stop cancer growth.
This Phase 2 trial studies whether giving immunotherapy along with a precise form of brain radiation can control brain metastases from non-small cell lung cancer. It may help by shrinking or stabilizing spots in the brain while your body’s immune system is also activated.
This trial tests whether adding nitroglycerin (a medicine that widens blood vessels) to standard whole-brain radiation helps improve treatment for lung cancer that has spread to the brain. It is for people with a specific gene change (EGFR mutation) in their cancer.
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.